[Efficacy and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure in routine practice].

Abstract

PURPOSE:

Evaluation of effectiveness and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure.

METHODS:

We conducted a retrospective and monocentric study. The evaluation of articular and cutaneous effectiveness by the patient was made with numeric scale and satisfaction scale and by the physician during a rhumatological-dermatological consultation. The safety was analyzed by collecting the adverse effects.

RESULTS:

Nine patients with anti-TNF failure were included. Five of them stopped the treatment because of severe adverse effects. The mean duration treatment of ustekinumab was 24 months. Articular and cutaneous effectiveness were respectively 4.4/10 and 6.7/10. Two thirds of the patients were "satisfied" and one third could stop any analgesic treatment. The mean PASI score decreased from 8.4 to 1.7 after 3 months treatment. Only minor adverse effects were collected and there were no recidivism of the adverse effects observed with anti-TNFα.

CONCLUSION:

Ustekinumab is an effective and safe alternative for patients with anti-TNFα failure in psoriatic arthritis.

• Authors: Matthias Michel, Ziad Reguiai, Marion Fauconier, Pascal Brochot, Jean-Paul Eschard, Jean-Hugues Salmon
• Journal: Therapie (Therapie) Vol. 71 Issue 3 Pg. 281-6 (Jun 2016) ISSN: 0040-5957 [Print] France
• Vernacular Title: Ustekinumab dans le rhumatisme psoriasique après échec des anti-TNFα en pratique courante.
• PMID: 27235651 (Publication Type: Journal Article)
• Copyright: Copyright © 2016 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Chemical References

• Dermatologic Agents
• Immunosuppressive Agents
• Tumor Necrosis Factor-alpha
• Ustekinumab

Topics

• Adult
• Aged
• Arthritis, Psoriatic (drug therapy, psychology)
• Dermatologic Agents (adverse effects, therapeutic use)
• Female
• Hand Dermatoses (chemically induced)
• Humans
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Male
• Middle Aged
• Patient Satisfaction
• Retrospective Studies
• Treatment Failure
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)
• Ustekinumab (adverse effects, therapeutic use)